tapebrief
DVA · Q1 2026

DVA · Q2 2026 Earnings

Neutral

DaVita

Reported August 4, 2026

30-second summary

Revenue grew 5.2% YoY to $3.55B and adjusted EPS of $4.02 beat consensus of $3.88 by 3.6%, with U.S. Dialysis treatments/day at 92,649 (+0.6% YoY per day) and patient care cost per treatment falling to $277.40 from Q1's $280.11 — the cost line resolved favorably. Despite the beat, FY2026 guidance was reaffirmed unchanged across EPS ($14.10–$15.20), adjusted OI ($2,150M–$2,250M), and FCF ($1,000M–$1,250M) — a conservative posture given Q2 delivered $256M of FCF and the FCF conversion path materially improved. IKC is the standout: revenue of $162M (+39.7% YoY) and risk-based patients rebuilding to 64,900 from Q1's 62,600 reversed the sequential contraction flagged last quarter.

Headline numbers

EPS

Q2 FY2026

$4.02

+3.6% vs est.

Revenue

Q2 FY2026

$3.55B

+5.2% YoY

+1.8% vs est.

Free cash flow

Q2 FY2026

$0.26B

Operating margin

Q2 FY2026

16.3%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$3.55B$3.38B+5.1%$3.42B+4.0%
EPS$4.02$2.95+36.3%$2.87+40.1%
Operating margin16.3%15.9%+40bps14.1%+220bps
Free cash flow$0.26B$0.16B+63.1%$0.14B+82.9%

Guidance

DaVita reaffirms full-year FY2026 guidance across EPS, adjusted operating income, and free cash flow despite strong Q2 beat.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Reaffirmed unchanged this quarter: Adjusted diluted EPS ($14.10 to $15.20), Adjusted operating income ($2,150 million to $2,250 million), Free cash flow ($1,000 million to $1,250 million)

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
U.S. Dialysis$3.012B$2.913B+3.4%
Integrated Kidney Care$0.162B—+39.7%
International$0.386B—+3.8%

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
U.S. Dialysis Treatments per Day92,64992,131—
U.S. Dialysis YoY Per Day Growth0.6%——
Normalized Non-Acquired Treatment Growth0.3%——
Revenue per Treatment$415.87$404.58—
Patient Care Cost per Treatment$277.40——
Total Patients Served298,500——
Risk-Based IKC Patients64,90064,400—
Annualized Risk-Based Medical Spend$5.8B$5.3 billion—

Management tone

No earnings call transcript was available for this quarter; tone commentary is limited to what can be inferred from the press release and the shift in disclosed qualitative language.

Q3-2025 quiet downward narrowing → Q4-2025 growth re-framing on non-organic drivers → Q1-2026 confident ahead-of-plan trilogy → Q2-2026 no forward color offered publicly.

The most notable qualitative shift is what is absent: DaVita's Q1 print carried detailed prepared remarks and Q&A from Rodriguez and Ackerman on Fresenius phasing, ACA effectuation, and technology investment. This quarter's press release opens with a one-line reference to "exciting new innovations in kidney dialysis to enhance the lives of our patients" — a shift in emphasis from the prior quarter's "clinical excellence" and "durable results" framing. Innovation language typically signals a strategic-growth posture rather than the operational-efficiency posture that has defined the last three prints.

The reaffirmed FY guide against a clean Q2 beat is itself a tone signal: management is unwilling to lift the range one quarter after raising it, even with cost-per-treatment resolving favorably and NAG holding positive. That is either a conservative posture ahead of ACA mid-year data or a signal that H2 headwinds (ACA effectuation, RPT mix normalization, IKC Q4 phasing) are being underwritten more cautiously than the Q2 optics would suggest.

Answers to last quarter's watch list

Patient care cost per treatment direction — Resolved favorably. Q2 printed $277.40 vs. Q1's $280.11, a $2.71 sequential decline that is well inside the $282 threshold flagged as the erosion trigger. The labor efficiency narrative held for a second consecutive quarter.
Resolved positively
Whether normalized NAG sustains positive once the Fresenius new-start tailwind is fully absorbed by Q3 — Two consecutive positive prints (Q1 +0.1%, Q2 +0.3%), with Q2 treatments/day accelerating +1,000 sequentially — consistent with management's prior framing that the second half of the Fresenius benefit came in Q2. The Q3 print remains the cleaner test of underlying volume once the transfer tailwind is fully absorbed.
Continue monitoring
IKC risk-based patient count and managed spend recovery — Resolved favorably. Risk-based patients rebuilt to 64,900 from Q1's 62,600 (+2,300 sequentially), and annualized managed spend rose to $5.8B from $5.4B. Both metrics now sit above Q4 2025 levels (66,000 / $5.6B on patients was the peak — Q2 is slightly below on patients but above on spend). The Q1 sequential contraction was a one-quarter phenomenon, not a trend.
Resolved positively
Q2 FCF run-rate against the implied $860M–$1.11B Q2–Q4 requirement — Q2 FCF of $256M cleared the ~$200M lower-bound flagged in the watch list. H1 total FCF is now $396M; H2 requirement to hit the reaffirmed FY range is $604M–$854M. The trajectory is credible after being marginal one quarter ago.
Resolved positively
ACA effectuation and mix as enrollment data matures — The company did not disclose updated ACA effectuation or mix commentary in the press release, and no transcript is available to check for Q&A color. The reaffirmed guide despite the beat suggests management is not yet ready to move on the $40M assumption.
Continue monitoring

What to watch into next quarter

Q3 normalized NAG once the Fresenius new-start tailwind is fully in the base — management previously said two-thirds of the annual Fresenius benefit lands by mid-year. Q3 is the cleanest read of underlying volume without the transfer tailwind carrying the print. A Q3 NAG below +0.2% would suggest the H1 improvement was largely mechanical.

Whether the FY EPS guide is finally raised on the Q3 print — H1 EPS of $6.89 against a $14.65 midpoint implies H2 EPS of $7.76. A Q3 print of $3.50+ combined with continued cost discipline would force a guide raise or expose management as unwilling to move the range regardless of results.

Patient care cost per treatment holding below $280 — Q2 at $277.40 rebuilt the cushion; a Q3 print above $280 would signal the labor efficiency lever is oscillating rather than durably improving.

IKC OI trajectory into the Q4-loaded phasing — patient count and managed spend both recovered in Q2. The next test is whether the ~$20M FY IKC OI target holds as we approach the Q4 phasing weight.

ACA mid-year visibility and any commentary on the $40M 2026 headwind assumption — the Q3 print will have effectuation and payment-performance data that Q2 lacked; a revision to the headwind assumption in either direction would be a discrete guide input.

Sources

  1. DaVita Inc. Q2 FY2026 Earnings Press Release (SEC Form 8-K Exhibit 99.1), filed 2026-08-04.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.